WO2005001022A3 - Methods and compositions for enhancing immune response - Google Patents
Methods and compositions for enhancing immune response Download PDFInfo
- Publication number
- WO2005001022A3 WO2005001022A3 PCT/US2004/011085 US2004011085W WO2005001022A3 WO 2005001022 A3 WO2005001022 A3 WO 2005001022A3 US 2004011085 W US2004011085 W US 2004011085W WO 2005001022 A3 WO2005001022 A3 WO 2005001022A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- methods
- immune response
- enhancing immune
- irm
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04775877A EP1617872A4 (en) | 2003-04-10 | 2004-04-09 | Methods and compositions for enhancing immune response |
JP2006532393A JP2007514644A (en) | 2003-04-10 | 2004-04-09 | Methods and compositions for improving immune response |
CA002521662A CA2521662A1 (en) | 2003-04-10 | 2004-04-09 | Methods and compositions for enhancing immune response |
AU2004252409A AU2004252409A1 (en) | 2003-04-10 | 2004-04-09 | Methods and compositions for enhancing immune response |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46214003P | 2003-04-10 | 2003-04-10 | |
US60/462,140 | 2003-04-10 | ||
US10/640,904 US7427629B2 (en) | 2002-08-15 | 2003-08-14 | Immunostimulatory compositions and methods of stimulating an immune response |
US10/640,904 | 2003-08-14 | ||
US51525603P | 2003-10-29 | 2003-10-29 | |
US60/515,256 | 2003-10-29 | ||
US53370303P | 2003-12-31 | 2003-12-31 | |
US60/533,703 | 2003-12-31 | ||
US54554204P | 2004-02-18 | 2004-02-18 | |
US54542404P | 2004-02-18 | 2004-02-18 | |
US60/545,542 | 2004-02-18 | ||
US60/545,424 | 2004-02-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005001022A2 WO2005001022A2 (en) | 2005-01-06 |
WO2005001022A3 true WO2005001022A3 (en) | 2005-09-15 |
Family
ID=34923557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/011085 WO2005001022A2 (en) | 2003-04-10 | 2004-04-09 | Methods and compositions for enhancing immune response |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1617872A4 (en) |
JP (1) | JP2007514644A (en) |
AU (1) | AU2004252409A1 (en) |
CA (1) | CA2521662A1 (en) |
WO (1) | WO2005001022A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9314535B2 (en) | 2009-09-03 | 2016-04-19 | Curevac Ag | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
US9572874B2 (en) | 2008-09-30 | 2017-02-21 | Curevac Ag | Composition comprising a complexed (M)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US11965000B2 (en) | 2013-08-21 | 2024-04-23 | CureVac SE | Respiratory syncytial virus (RSV) vaccine |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006007433A1 (en) * | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Immunostimulant adjuvant useful in vaccines against cancer or infectious diseases comprises a lipid-modified nucleic acid |
JP2010507361A (en) | 2006-07-31 | 2010-03-11 | キュアバック ゲーエムベーハー | Specifically, a nucleic acid represented by the general formula (I): GlXmGn or the general formula (II): ClXmCn as an immunostimulant / adjuvant |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
SG188104A1 (en) | 2008-01-31 | 2013-03-28 | Curevac Gmbh | Nucleic acids comprising formula (nuglxmgnnv)a and derivatives thereof as an immunostimulating agents /adjuvants |
ES2656813T3 (en) | 2008-10-24 | 2018-02-28 | Glaxosmithkline Biologicals Sa | Lipidated Imidazoquinoline Derivatives |
BR112013002298A2 (en) | 2010-07-30 | 2016-05-24 | Curevac Gmbh | nucleic acid complexation with disulfide crosslinked cationic components for transfection and immune stimulation. |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
EP3065741B1 (en) | 2013-11-05 | 2021-09-22 | 3M Innovative Properties Company | Sesame oil based injection formulations |
US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
WO2017056494A1 (en) | 2015-09-29 | 2017-04-06 | Sumitomo Dainippon Pharma Co., Ltd. | Adenine conjugate compounds and their use as vaccine adjuvants |
JP6769976B2 (en) | 2015-10-07 | 2020-10-14 | 大日本住友製薬株式会社 | Pyrimidine compound |
MA44334A (en) | 2015-10-29 | 2018-09-05 | Novartis Ag | ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST |
AU2017292934B2 (en) | 2016-07-07 | 2024-04-04 | Bolt Biotherapeutics, Inc. | Antibody adjuvant conjugates |
BR112021001188A8 (en) | 2018-07-23 | 2022-12-06 | Japan As Represented By The Director General Of Nat Institute Of Infectious Diseases | COMPOSITION CONTAINING INFLUENZA VACCINE |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447724A (en) * | 1990-05-17 | 1995-09-05 | Harbor Medical Devices, Inc. | Medical device polymer |
US6486214B1 (en) * | 1997-09-10 | 2002-11-26 | Rutgers, The State University Of New Jersey | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
US6486168B1 (en) * | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
US6518280B2 (en) * | 1998-12-11 | 2003-02-11 | 3M Innovative Properties Company | Imidazonaphthyridines |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194581A (en) * | 1989-03-09 | 1993-03-16 | Leong Kam W | Biodegradable poly(phosphoesters) |
US5342940A (en) * | 1989-05-27 | 1994-08-30 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, process for preparing the same |
US5858397A (en) * | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
CA2361936C (en) * | 1999-01-08 | 2009-06-16 | 3M Innovative Properties Company | Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions |
CA2430206A1 (en) * | 2000-12-08 | 2002-06-13 | 3M Innovative Properties Company | Screening method for identifying compounds that selectively induce interferon alpha |
CN1292751C (en) * | 2002-04-23 | 2007-01-03 | 四川大学 | Imiquimod or its derivative liposome for local skin and its preparing method and use |
ATE488246T1 (en) * | 2002-08-15 | 2010-12-15 | 3M Innovative Properties Co | IMMUNO-STIMULATORY COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE |
WO2004060967A1 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Methods for the formation of hydrogels using thiosulfonate compositions and uses thereof |
-
2004
- 2004-04-09 CA CA002521662A patent/CA2521662A1/en not_active Abandoned
- 2004-04-09 WO PCT/US2004/011085 patent/WO2005001022A2/en active Application Filing
- 2004-04-09 JP JP2006532393A patent/JP2007514644A/en not_active Withdrawn
- 2004-04-09 AU AU2004252409A patent/AU2004252409A1/en not_active Abandoned
- 2004-04-09 EP EP04775877A patent/EP1617872A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447724A (en) * | 1990-05-17 | 1995-09-05 | Harbor Medical Devices, Inc. | Medical device polymer |
US6486214B1 (en) * | 1997-09-10 | 2002-11-26 | Rutgers, The State University Of New Jersey | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
US6518280B2 (en) * | 1998-12-11 | 2003-02-11 | 3M Innovative Properties Company | Imidazonaphthyridines |
US6486168B1 (en) * | 1999-01-08 | 2002-11-26 | 3M Innovative Properties Company | Formulations and methods for treatment of mucosal associated conditions with an immune response modifier |
Non-Patent Citations (2)
Title |
---|
GIBSON S.J. ET AL: "Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod", CELL IMMUNOL, vol. 218, 2002, pages 74 - 86, XP002985828 * |
See also references of EP1617872A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9572874B2 (en) | 2008-09-30 | 2017-02-21 | Curevac Ag | Composition comprising a complexed (M)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US9314535B2 (en) | 2009-09-03 | 2016-04-19 | Curevac Ag | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
US11965000B2 (en) | 2013-08-21 | 2024-04-23 | CureVac SE | Respiratory syncytial virus (RSV) vaccine |
Also Published As
Publication number | Publication date |
---|---|
EP1617872A2 (en) | 2006-01-25 |
WO2005001022A2 (en) | 2005-01-06 |
EP1617872A4 (en) | 2011-09-07 |
AU2004252409A1 (en) | 2005-01-06 |
JP2007514644A (en) | 2007-06-07 |
CA2521662A1 (en) | 2005-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005001022A3 (en) | Methods and compositions for enhancing immune response | |
WO2005055932A3 (en) | Therapeutic combinations and methods including irm compounds | |
WO2006031878A3 (en) | Imidazoquinoline compounds | |
WO2004041170A9 (en) | Compositions and methods for the treatment of immune related diseases | |
WO2004082822A3 (en) | Methods for isolating crystalline form i of 5-azacytidine | |
WO2006130399A3 (en) | Therapeutic combinations and methods including irm compounds | |
WO2005019258A3 (en) | Compositions and methods for the treatment of immune related diseases | |
WO2004024097A9 (en) | Compositions and methods for the treatment of immune related diseases | |
WO2004078138A3 (en) | Prophylactic treatment of uv-induced epidermal neoplasia | |
WO2003051294A3 (en) | Mitocidal compositions and methods | |
PL378571A1 (en) | Active immunization to generate antibodies to soluble a-beta | |
WO2004037194A3 (en) | Novel compositions with chitinase activity | |
EP1516612A3 (en) | Two-step mascara | |
WO2005021497A3 (en) | Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones | |
EP1550448A4 (en) | Histamine release inhibitor | |
WO2003099217A3 (en) | Methods of treating bacterial infections and diseases associated therewith | |
WO2000077206A3 (en) | The myostatin gene promoter and inhibition of activation thereof | |
WO2004087073A3 (en) | Treatment of demyelinating conditions | |
WO2005051083A3 (en) | Molluscicidal and anti-barnacle compounds | |
EP1344515A4 (en) | Skin cosmetics | |
WO2004024072A3 (en) | Novel compositions and methods for the treatment of immune related diseases | |
WO2008139952A1 (en) | Microtubule-disrupting agent and cancer cell proliferation inhibitor containing the same | |
AU2003212344A1 (en) | Use of extracts from olive trees as anti-dandruff agents | |
WO2004100873A3 (en) | Compounds, compositions, and methods | |
WO2005005382A3 (en) | Compounds, compositions and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2521662 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004252409 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006532393 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2004252409 Country of ref document: AU Date of ref document: 20040409 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004252409 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004775877 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004775877 Country of ref document: EP |